Climb Bio (stock code: CLYM) announced today that the U.S. Food and Drug Administration (FDA) has granted its candidate drug Budoprutug Fast Track designation for the treatment of primary membranous nephropathy.
Show original
Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!
A welcome pack worth 6200 USDT for new users! Sign up now!
This designation will accelerate the review process for the drug, offering patients the possibility of earlier access to innovative therapies. Primary membranous nephropathy is an autoimmune kidney disease with limited treatment options. Fast Track designation aims to promote the development and review of drugs for serious diseases where medical needs have not been met. Climb Bio stated it will continue advancing the clinical development plan for Budoprotigide.
0
0
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
Understand the market, then trade.
Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.
Trade now!
You may also like
Bitcoin Having Best September Since 2012
UToday•2026/09/23 16:57
Micron's Chip Shortage Expected to Deepen Into 2027 as Demand Surges, UBS Says
MT newswire•2026/09/23 16:55
BUZZ - Voyager Technologies shares drop due to planned convertible bond deal
路透社•2026/09/23 16:51
Ex-Gold Fields CEO targets $1B Africa critical minerals fund
Mining.com•2026/09/23 16:51
Crypto prices
MoreBitcoin
BTC
$83,870.37
-3.04%
Ethereum
ETH
$2,656.08
-3.38%
Tether USDt
USDT
$0.9999
-0.02%
BNB
BNB
$764.25
-3.29%
XRP
XRP
$1.49
-4.84%
USDC
USDC
$0.9996
-0.03%
Solana
SOL
$113.96
-3.16%
TRON
TRX
$0.3388
-0.56%
Zcash
ZEC
$1,531.52
-1.63%
Hyperliquid
HYPE
$92.42
-3.19%
How to buy BTC
Bitget lists BTC – Buy or sell BTC quickly on Bitget!
Trade now
Become a trader now?A welcome pack worth 6200 USDT for new users!
Sign up now